Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
  • Patent number: 10392604
    Abstract: The present invention relates to the field of medicine and virology. An attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof are provided, which can be used for the prevention and/or treatment of an infectious disease. In addition, the present invention relates to an attenuated influenza A virus, an influenza virus vector based thereon, and a pharmaceutical composition comprising thereof, which can be used for the treatment of oncological diseases.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: August 27, 2019
    Assignee: PHARMENTERPRISES BIOTECH Limited Liability Company
    Inventors: Andrei Yurievich Egorov, Boris Ferko, Artem Alexandrovich Krokhin, Yulia Romanovna Romanova
  • Patent number: 10369213
    Abstract: Methods for improving the drying yield and stability of RSV vaccines comprising a highly thermolabile enveloped live virus and/or one or more RSV protein subunits, are described. Methods for rapid drying of RSV formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. The disclosed methods provide for; 1) a dried RSV formulation with improved stability profile; 2) faster drying; and 3) integration of dried RSV into a primary device (such as dual chamber cartridges, foil-pouch devices etc.), pre- as well as post-drying.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Lynne A. Isopi
  • Patent number: 10344261
    Abstract: The present invention provides an immunomodulatory compound comprising a carbohydrate polymer comprising mannose, wherein the carbohydrate polymer is conjugated to at least one immune modulator. The present invention also provides for the use of this compound in immunomodulatory compositions for vaccination and gene therapy methods, together with processes for its preparation.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: July 9, 2019
    Assignee: ASCEND BIOPHARMACEUTICALS LTD
    Inventors: Geoffrey Alan Pietersz, Clement Leong
  • Patent number: 10273462
    Abstract: The present invention provides viral vector compositions of high titer and purity, as well as methods for production of said compositions. The methods of the invention incorporate multiple features, such as production of viral vector particles in serum free media and multiple harvesting steps following transduction of the producer cell which provides for enhanced production of said viral vectors. The viral vector compositions of the invention, by virtue of their high titer and purity, minimize the deleterious phenotypic changes that typically occur following transduction of target cells, such as loss of a sub-populations of transduced cells, and effects on proliferation, differentiation, reprogramming or functionality of transduced cells.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 30, 2019
    Assignee: Vectalys SAS
    Inventors: Pascale Bouillé, Hélène Vergnault, Régis Gayon, Yohann Moal
  • Patent number: 10232031
    Abstract: New influenza donor strains for the production of reassortant influenza B viruses are provided.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 19, 2019
    Assignees: Seqirus UK Limited, Synthetic Genomics, Inc.
    Inventors: Philip Dormitzer, Peter Mason, Pirada Suphaphiphat, Raul Gomila
  • Patent number: 10080778
    Abstract: Five tetra peptides corresponding to different active regions of brain derived neurotrophic factor (BDNF) that are neurotrophic and can modulate BDNF signaling in a partial agonist/antagonist way. The peptides offer a therapeutic approach to neural pathologies where BDNF levels are dysregulated.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: September 25, 2018
    Assignee: Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 9981034
    Abstract: Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza A. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition. In certain aspects, the immunogenic composition is a vaccine comprised of a recombinant chimeric hemagglutinin polypeptide. In certain aspects, the subject is a mammal. In further aspects, the mammal is a pig. In still further aspects, the mammal is a human.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: May 29, 2018
    Assignee: South Dakota Board of Regents
    Inventors: Victor Huber, Ying Fang
  • Patent number: 9975925
    Abstract: Novel influenza antigens, novel immunogenic or vaccine compositions, as well as uses of and methods for producing said antigens and compositions, are described.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: May 22, 2018
    Assignees: GLAXOSMITHKLINE BIOLOGICALS S.A., THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT. HEALTH & HUMAN SERVICES
    Inventors: James Stevens, Ruben Donis, David Shore, Hongquan Wan, Ventzislav Bojidarov Vassilev
  • Patent number: 9969984
    Abstract: Herein is provided a recombinant lentiviral vector preparation, in which the preparation comprises: a) an effective dose of the recombinant lentiviral vector; b) a histidine hydrochloride buffer for keeping a pH value of the preparation in the range of 6.0-8.0; and c) a carbohydrate.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: May 15, 2018
    Assignee: BEIJING SOLOBIO GENETECHNOLOGY COMPANY LTD.
    Inventors: Jundie Fan, Lixin Jiang, Zhiwen Zhou
  • Patent number: 9943588
    Abstract: The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol and/or a tocopherol such as alpha tocopherol, and an emulsifying agent.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 17, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Emmanuel Jules Hanon, Jean Stephenne
  • Patent number: 9901634
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 27, 2018
    Assignee: NOVAVAX AB
    Inventors: Bror Morein, Karin Lovgren Bengtsson
  • Patent number: 9855328
    Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to recombinant human adenovirus vectors for delivery of avian immunogens and antigens, such as avian influenza into avians. The invention also provides methods of introducing and expressing an avian immunogen in avian subjects, including avian embryos, as well as methods of eliciting an immunogenic response in avian subjects to avian immunogens.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 2, 2018
    Assignees: AUBURN UNIVERSITY, ALTIMMUNE INC.
    Inventors: De-Chu C. Tang, Kent R. Van Kampen, Haroldo Toro
  • Patent number: 9821064
    Abstract: Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilization.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: November 21, 2017
    Assignee: GE HEALTHCARE BIO-SCIENCES CORP.
    Inventors: Tianxiao Sun, Philip M. Levesque, Alicja T. Brown, Cynthia K. Lee
  • Patent number: 9775911
    Abstract: The present invention provides among other things a composition of a polymeric reagent and an antioxidant, such as butylated hydroxyl toluene.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 3, 2017
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
  • Patent number: 9730999
    Abstract: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: August 15, 2017
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Emmanuel Jules Hanon, Jean Stephenne
  • Patent number: 9708585
    Abstract: New influenza donor strains for the production of reassortant influenza A viruses are provided.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: July 18, 2017
    Assignee: Seqirus UK Limited
    Inventors: Peter Mason, Philip Ralph Dormitzer, Heidi Trusheim, Pirada Suphaphiphat
  • Patent number: 9657359
    Abstract: The invention relates to generic methods for the detection and quantification of mammalian reoviruses. These may uses a reverse transcription (RT-PCR) real time (q-PCR) assay which amplifies a conserved region within all MRV types. The assays allow the quantification of MRV RNA molecules, irrespective of the particular virus type (e.g. MRV-1, MRV-2). The methods are particularly applicable in the monitoring of vaccine production processes.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: May 23, 2017
    Assignee: Novartis AG
    Inventor: Bernhard Roth
  • Patent number: 9637522
    Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: May 2, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Yuan Lu, James R. Swartz
  • Patent number: 9623105
    Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: April 18, 2017
    Assignee: MERIAL, INC.
    Inventor: Benjamin M. Hause
  • Patent number: 9623104
    Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 18, 2017
    Assignee: NOVAVAX, INC.
    Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
  • Patent number: 9441207
    Abstract: Animal cells are described which can be infected by viruses and which are adapted to growth in suspension in medium free of animal-derived components, such as serum-free medium. Processes for the replication of viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the viruses or antigenic portions thereof obtainable by the process.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Intervet Inc.
    Inventors: Monty R. Warthen, William F. Skotta
  • Patent number: 9410212
    Abstract: The invention relates to a method of detecting the presence of Salmonella in a sample using novel oligonucleotide sequences. Also presented is a kit for putting the method into practice and novel nucleic acid sequences for ompF. The ompF gene was found to be 100% inclusive for Salmonella species and 100% exclusive for non-Salmonella species for the strains tested thus making it an excellent marker for identification of both the species of Salmonella: S. enterica and S. bongori. Two hundred and eighteen isolates belonging to Salmonella enterica (subspecies I-VI) and Salmonella bongori were examined using novel primers designed to detect the ompF gene. The target was present in all the 218 Salmonella isolates including all the subspecies of Salm. enterica and Salm. bongori. The ompF gene was absent in 180 non-Salmonella strains tested.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 9, 2016
    Assignee: University of South Florida
    Inventors: Aparna Tatavarthy, Andrew C. Cannons, Loree C. Heller
  • Patent number: 9403878
    Abstract: Methods for producing virus particles with simplified glycosylation on structural or surface proteins, such as mono-glycosylated forms of influenza A virus, NIBRG-14 (H5N1). When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations. Such methods may include the use of glycosylation inhibitors for production of viruses with simplified glycosylation profiles.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 2, 2016
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Che Ma, Yung-Chieh Tseng
  • Patent number: 9327137
    Abstract: The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: May 3, 2016
    Assignee: MERIAL, INC.
    Inventors: Jean-Christophe Audonnet, Jules Minke
  • Patent number: 9278126
    Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
    Type: Grant
    Filed: February 10, 2010
    Date of Patent: March 8, 2016
    Assignee: Seqirus UK Limited
    Inventors: Mario Contorni, Derek O'hagan, Nicola Groth
  • Patent number: 9216211
    Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: December 22, 2015
    Assignee: MERIAL, INC.
    Inventor: Benjamin M Hause
  • Patent number: 9150620
    Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: October 6, 2015
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Shih-Chang Lin
  • Patent number: 9138471
    Abstract: The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.
    Type: Grant
    Filed: October 12, 2011
    Date of Patent: September 22, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Nathalie Garcon, Moncef Mohamed Slaoui, Christian Van Hoecke
  • Patent number: 9089537
    Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: July 28, 2015
    Assignees: The Trustees of the University of Pennslyvania, Juvaris Biotherapeutics, Inc.
    Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
  • Patent number: 9072701
    Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: July 7, 2015
    Assignees: St. Jude Children's Research Hospital, Zoetis Services LLC
    Inventors: Erich Hoffmann, Scott L. Krauss, Mahesh Kumar, Richard J. Webby, Robert G. Webster
  • Patent number: 9040296
    Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.
    Type: Grant
    Filed: March 17, 2012
    Date of Patent: May 26, 2015
    Assignee: Valneva
    Inventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
  • Publication number: 20150140036
    Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
    Type: Application
    Filed: November 13, 2014
    Publication date: May 21, 2015
    Applicant: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.
    Inventors: Joan Mannick, David Glass, Leon Murphy
  • Patent number: 9028838
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: May 12, 2015
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • Patent number: 9023319
    Abstract: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: May 5, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Michael Decker
  • Publication number: 20150118264
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: April 30, 2015
    Applicant: CureVac GMBH
    Inventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Patent number: 9011874
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 21, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
  • Patent number: 9005632
    Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: April 14, 2015
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
  • Patent number: 9005623
    Abstract: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: April 14, 2015
    Assignee: Sanofi Pasteur, SA
    Inventors: Catherine Moste, Isabelle Legastelois, Michel Chevalier, Laurent Thion
  • Patent number: 9005621
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Publication number: 20150098966
    Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 9, 2015
    Applicant: KJ Biosciences LLC
    Inventors: Yawei Ni, Jianhua Guo
  • Patent number: 8999352
    Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: April 7, 2015
    Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as represented by the Secretary of Agriculture
    Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
  • Patent number: 8999353
    Abstract: A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: April 7, 2015
    Assignee: CSL Limited
    Inventors: Martin Pearse, Steve Rockman, David Ryan
  • Patent number: 8993624
    Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 31, 2015
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
  • Patent number: 8992939
    Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: March 31, 2015
    Assignee: Novavax, Inc.
    Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margret Nathan, Thomas Kort, Robin Robinson
  • Publication number: 20150086560
    Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.
    Type: Application
    Filed: September 21, 2014
    Publication date: March 26, 2015
    Inventors: Mark R. AIfenito, Mark Baer, Doris Bucher
  • Publication number: 20150086587
    Abstract: Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 26, 2015
    Inventors: Jishu Shi, Loretta Pappan, Amy Beckley, Qixin Zhong
  • Patent number: 8986705
    Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: George Robert Trager, Vu Truong-Le, Luisa Yee
  • Patent number: 8986987
    Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: March 24, 2015
    Assignee: Intervet Inc.
    Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
  • Patent number: 8980281
    Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: March 17, 2015
    Assignee: Academia Sinica
    Inventors: Pei-Wen Hsiao, Chia-Ying Wu, Yi-Chun Yeh
  • Publication number: 20150064216
    Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.
    Type: Application
    Filed: November 11, 2014
    Publication date: March 5, 2015
    Inventors: William A. CARTER, David STRAYER